These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 1863402)

  • 1. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.
    Willey S; Aasa-Chapman MM; O'Farrell S; Pellegrino P; Williams I; Weiss RA; Neil SJ
    Retrovirology; 2011 Mar; 8():16. PubMed ID: 21401915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved microtiter assay for evaluating anti-HIV-1 neutralizing antibodies from sera or plasma.
    Zhang C; Chen Y; Ben K
    BMC Infect Dis; 2003 Dec; 3():30. PubMed ID: 14693038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development.
    Beck Z; Prohászka Z; Füst G
    Vaccine; 2008 Jun; 26(24):3078-85. PubMed ID: 18241961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.
    Subbramanian RA; Xu J; Toma E; Morisset R; Cohen EA; Menezes J; Ahmad A
    J Clin Microbiol; 2002 Jun; 40(6):2141-6. PubMed ID: 12037078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.
    Prohászka Z; Tóth FD; Bánhegyi D; Füst G
    Pathol Oncol Res; 1997; 3(4):296-302. PubMed ID: 11173651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells.
    Moir S; Malaspina A; Li Y; Chun TW; Lowe T; Adelsberger J; Baseler M; Ehler LA; Liu S; Davey RT; Mican JA; Fauci AS
    J Exp Med; 2000 Sep; 192(5):637-46. PubMed ID: 10974030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.
    Montefiori DC
    Springer Semin Immunopathol; 1997; 18(3):371-90. PubMed ID: 9089955
    [No Abstract]   [Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.
    McElrath MJ; Corey L; Greenberg PD; Matthews TJ; Montefiori DC; Rowen L; Hood L; Mullins JI
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):3972-7. PubMed ID: 8633000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    Trkola A; Purtscher M; Muster T; Ballaun C; Buchacher A; Sullivan N; Srinivasan K; Sodroski J; Moore JP; Katinger H
    J Virol; 1996 Feb; 70(2):1100-8. PubMed ID: 8551569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of human immunodeficiency virus infection.
    Levy JA
    Microbiol Rev; 1993 Mar; 57(1):183-289. PubMed ID: 8464405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity.
    Huang LM; Joshi A; Willey R; Orenstein J; Jeang KT
    EMBO J; 1994 Jun; 13(12):2886-96. PubMed ID: 8026473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell responses to HIV and the development of human monoclonal antibodies.
    Boyd JE; James K
    Clin Exp Immunol; 1992 May; 88(2):189-202. PubMed ID: 1572084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Kliks S; Wright PF
    J Clin Immunol; 1992 Nov; 12(6):429-39. PubMed ID: 1287035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group.
    Montefiori DC; Lefkowitz LB; Keller RE; Holmberg V; Sandstrom E; Phair JP
    AIDS; 1991 May; 5(5):513-7. PubMed ID: 1863402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease.
    Füst G; Tóth FD; Kiss J; Ujhelyi E; Nagy I; Bánhegyi D
    AIDS; 1994 May; 8(5):603-9. PubMed ID: 7914732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.
    Tóth FD; Szabó B; Ujhelyi E; Pálóczi K; Horváth A; Füst G; Kiss J; Bánhegyi D; Hollán SR
    AIDS; 1991 Mar; 5(3):263-8. PubMed ID: 1676275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement-mediated, antibody-dependent neutralizing titers of sera from asymptomatic and symptomatic HIV-infected individuals.
    Spear GT; Carlson JR; Jennings MB; Takefman DM; Landay AL
    AIDS; 1992 Sep; 6(9):1047. PubMed ID: 1388899
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of neutralizing antibodies in HIV infection.
    Humbert M; Dietrich U
    AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement, Fc receptors and antibodies: a Trojan horse in HIV infection?
    Stoiber H
    Curr Opin HIV AIDS; 2009 Sep; 4(5):394-9. PubMed ID: 20048703
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.